

02 February 2026

Oxford Nanopore Technologies plc (the "Company")

Issue of Equity and Total Voting Rights

The Company today announces in respect of the month ended 31 January 2026, the issue of 850,633 ordinary shares of £0.0001 each ("Ordinary Shares"), following the exercise of options granted under the Company's share option plans and issuance of shares under certain of the Company's remuneration schemes.

Such Ordinary Shares were also admitted to the Official List of the Financial Conduct Authority ("FCA") and to trading on the London Stock Exchange's main market for listed securities under the Company's block listing facility. Following this issue, the Company has the ability to admit a further 5,617,546 Ordinary Shares under its block listing facility.

In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company announces that as at 31 January 2026, the Company's issued share capital consisted of 966,907,658 Ordinary Shares. The Company did not hold any shares in treasury. Accordingly, the total number of voting rights in the Company as at 31 January 2026 is 966,907,658. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Investors
ir@nanoporetech.com

Media
media@nanoporetech.com
OxfordNanoporeTechnologies@teneo.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seq.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVREALAAEAEKAFA